This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1977 Oct;4(5):630P.

doi: 10.1111/j.1365-2125.1977.tb00802.x.

Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings]

R A Branch, D M Kornhauser, D G Shand, G R Wilkinson, A J Wood

PMID: 911615
DOI: 10.1111/j.1365-2125.1977.tb00802.x

Free article

Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings]

R A Branch et al. Br J Clin Pharmacol. 1977 Oct.

Free article

. 1977 Oct;4(5):630P.

doi: 10.1111/j.1365-2125.1977.tb00802.x.

Authors

R A Branch, D M Kornhauser, D G Shand, G R Wilkinson, A J Wood

PMID: 911615
DOI: 10.1111/j.1365-2125.1977.tb00802.x

No abstract available

PubMed Disclaimer

Similar articles

Propranolol disposition in cirrhosis.
Jones DB. Jones DB. Gut. 1985 Aug;26(8):865. doi: 10.1136/gut.26.8.865. Gut. 1985. PMID: 4018653 Free PMC article. No abstract available.
[Study of bioavailability parameters of propranolol in cirrhotic patients after oral administration of the delayed-action form].
Blanc M, Cales P, Grasset D, Ravaud A, Meskens C, Cotonat J, Pascal JP. Blanc M, et al. Therapie. 1987 Mar-Apr;42(2):187-91. Therapie. 1987. PMID: 3616995 French. No abstract available.
Circadian bioavailability and some effects of propranolol in healthy subjects and in liver cirrhosis.
Semenowicz-Siuda K, Markiewicz A, Korczyńska-Wardecka J. Semenowicz-Siuda K, et al. Int J Clin Pharmacol Ther Toxicol. 1984 Dec;22(12):653-8. Int J Clin Pharmacol Ther Toxicol. 1984. PMID: 6526540
Propranolol disposition in chronic liver disease: a physiological approach.
Branch RA, Shand DG. Branch RA, et al. Clin Pharmacokinet. 1976;1(4):264-79. doi: 10.2165/00003088-197601040-00002. Clin Pharmacokinet. 1976. PMID: 797499 Review.
Pharmacokinetic-hemodynamic interactions in cirrhosis.
Blei AT. Blei AT. Semin Liver Dis. 1986 Nov;6(4):299-308. doi: 10.1055/s-2008-1040612. Semin Liver Dis. 1986. PMID: 3544223 Review. No abstract available.

See all similar articles

Cited by

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
Verbeeck RK. Verbeeck RK. Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61. doi: 10.1007/s00228-008-0553-z. Epub 2008 Sep 2. Eur J Clin Pharmacol. 2008. PMID: 18762933 Review.
beta-blocker plasma concentrations and inflammatory disease: clinical implications.
Schneider RE, Bishop H. Schneider RE, et al. Clin Pharmacokinet. 1982 Jul-Aug;7(4):281-4. doi: 10.2165/00003088-198207040-00001. Clin Pharmacokinet. 1982. PMID: 7116736 No abstract available.
Effect of hepatic insufficiency on pharmacokinetics and drug dosing.
Verbeeck RK, Horsmans Y. Verbeeck RK, et al. Pharm World Sci. 1998 Oct;20(5):183-92. doi: 10.1023/a:1008656930082. Pharm World Sci. 1998. PMID: 9820880 Review.
A standard approach to compiling clinical pharmacokinetic data.
Sheiner LB, Benet LZ, Pagliaro LA. Sheiner LB, et al. J Pharmacokinet Biopharm. 1981 Feb;9(1):59-127. doi: 10.1007/BF01059343. J Pharmacokinet Biopharm. 1981. PMID: 7014827
Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism.
Kelly JG, McDevitt DG. Kelly JG, et al. Br J Clin Pharmacol. 1978 Aug;6(2):123-7. doi: 10.1111/j.1365-2125.1978.tb00836.x. Br J Clin Pharmacol. 1978. PMID: 678388 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Wiley